NSE: ANURAS · 13 November 2026
- Anupam Rasayan India Ltd. (ANURAS) advanced by 8.22% on Thursday, closing at ₹1300.60 after trading within an intraday range of ₹1204.40 and ₹1306.00.
- The company reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, delivering consolidated quarterly revenue of ₹821 crore and an EBITDA of ₹202 crore. Profit after tax for the quarter stood at ₹65 crore, supported by strong performance across life sciences and performance materials segments. A revised financial filing with minor corrections was subsequently submitted on November 6, 2026.
- Trading volume was 3.82 times the 20-day average daily volume.
Why is Anupam Rasayan India share price rising on 13 November 2026?
Anupam Rasayan India Ltd. (ANURAS) advanced by 8.22% on Thursday, closing at ₹1300.60 after trading within an intraday range of ₹1204.40 and ₹1306.00.
The broader market and sector indices witnessed downward pressure during the trading session, with the Nifty falling 0.61% and the Nifty Metal sector benchmark dropping 0.98%. In contrast, Anupam Rasayan outperformed both benchmark indices significantly. Over the trailing 5-day and 20-day periods, the stock has posted returns of 12.92% and 9.57% respectively, reflecting firm medium-term momentum alongside the day's sharp upward surge.
Earlier in November, management also detailed ongoing strategic integration following its acquisition of a controlling stake in Bliss GVS Pharma and a long-term supply agreement with a US specialty metal manufacturer, though these developments act as broader operational context rather than direct same-day triggers.
17.39 lakh shares traded by 13 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 4.55 lakh shares (3.82 times). The five-day average daily volume was 6.36 lakh shares. Separately, the NSE report for 13 November 2026 showed 7.48 lakh shares delivered, representing 42.99% of that day’s traded volume. The same report recorded 56,551 trades.
The stock gained 8.22% on heavy volume that reached 3.82x the 20-day average, outperforming weak broader markets and sector benchmarks. While fundamental earnings and strategic updates provide constructive medium-term context, the sharp price and volume expansion reflect strong cash-market participation.
Latest Company Developments
The company reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, delivering consolidated quarterly revenue of ₹821 crore and an EBITDA of ₹202 crore. Profit after tax for the quarter stood at ₹65 crore, supported by strong performance across life sciences and performance materials segments. A revised financial filing with minor corrections was subsequently submitted on November 6, 2026.
Provides vital evidence of underlying revenue and margin growth following capacity expansion and recent business diversification.
Anupam Rasayan concluded the acquisition of a 50.07% controlling stake in Bliss GVS Pharma Limited on September 28, 2026. This transaction marks a strategic entry into finished dosage formulations, expanding the company's presence across the pharmaceutical value chain.
Enhances the company's product portfolio and geographic reach by integrating established pharmaceutical formulation capabilities.
During the second quarter, the company signed a six-year long-term supply contract with a leading US-based global specialty metal manufacturer. The agreement establishes Anupam Rasayan's presence in the geological resources sector and diversifies its customer base.
Secures multi-year revenue visibility and opens up a new industrial segment outside traditional agrochemicals and pharmaceuticals.
Revised Unaudited Financial Results (Standalone and Consolidated) of the Companyfor the quarter and half year ended September 30, 2026 with the correction of an inadvertent error.
update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS Pharma Limited.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 0.43% on 30 September 2026. This compares with 0.19% on 30 June 2026, a change of +0.24 percentage points.
The filing reported 20 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and financial integration progress of the newly acquired Bliss GVS Pharma subsidiary
- Ramp-up and shipment milestones under the newly signed six-year US specialty metal supply contract
- Sustained volume participation and delivery percentage relative to the 20-day average volume
- Quarterly earnings delivery and margin realization across Performance Materials and Pharmaceutical segments
More Anupam Rasayan India news and dated analysis →
Frequently Asked Questions
What is the latest Anupam Rasayan India company news?
The company reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, delivering consolidated quarterly revenue of ₹821 crore and an EBITDA of ₹202 crore. Profit after tax for the quarter stood at ₹65 crore, supported by strong performance across life sciences and performance materials segments. A revised financial filing with minor corrections was subsequently submitted on November 6, 2026.
How strong was Anupam Rasayan India’s trading volume?
17.39 lakh shares traded, 3.82 times the 20-day average daily volume. The price and volume data are dated 13 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.